Monday, December 22, 2008

UCB receives U.S. FDA Complete Response Letter for Neupro in Restless Legs Syndrome and Advanced Parkinson's disease

UCB announced today that it has received a Complete Response Letter from the U.S FDA for its transdermal patch, Neupro (rotigotine transdermal system) to treat the signs and symptoms of advanced Parkinson's disease, and as a treatment for the signs and symptoms of moderate to severe primary Restless Legs Syndrome.

the details can be read here.

No comments: